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Abstract
Introduction: Male breast cancer is rare compared to its female counterpart representing less
than 1% of cancer in men. Moreover, mucinous carcinoma of the male breast is an extremely rare
histological subtype of malignancy. Paget's disease of the nipple is rarely observed in males.
Case report: Herein, we describe a unique case of an 86 years old man with mucinous breast
cancer presenting as Paget's disease of the nipple. According to the immunohistochemical
evaluation the neoplastic cells were positive for estrogen (ER) and progesterone receptors (PR).
Conclusion:  To our best knowledge this is the first case of mucinous male breast cancer
presenting as Paget's disease of the nipple.
Background
The existing epidemiological data confirms the infre-
quency of male breast cancer (MBC) which represents 1%
of all breast cancers [1,2] Overall, the epidemiology of
MBC presents similarities with the epidemiology of
female breast cancer (FBC). Major genetic factors associ-
ated with an increased risk of breast cancer for men
include BRCA2 mutations, which are believed to account
for the majority of inherited breast cancer in men [3],
Klinefelter syndrome, and a family history. Suspected
genetic factors include AR gene mutations, CYP17 poly-
morphism, Cowden syndrome, and CHEK2 [3]. Epidemi-
ologic risk factors for MBC include disorders relating to
hormonal imbalances, such as obesity, testicular disorders
(e.g., cryptorchidism, mumps orchitis, and orchiectomy),
and radiation exposure. Suspected epidemiologic risk fac-
tors include prostate cancer, prostate cancer treatment,
gynecomastia, occupational exposures (e.g., electromag-
netic fields, polycyclic aromatic hydrocarbons, and high
temperatures), dietary factors (e.g., meat intake and fruit
and vegetable consumption), and alcohol intake [3].
Paget's disease presents as an eczematous change of the
nipple and areola [4]. Specifically, it is characterized by a
red, oozing, crusted lesion which is often unresponsive to
topical steroid and antibiotics. There is almost always
present an underlying breast carcinoma. The prevalence of
an associated cancer ranges from 67–100% with most
studies reporting the presence of a concurrent malignancy
in over 90% of patients [5]. Most commonly, this is an
infiltrating ductal carcinoma but occasionally a ductal car-
cinoma in situ (DCIS) may be present [4]. Overall, this
Published: 24 October 2008
Diagnostic Pathology 2008, 3:42 doi:10.1186/1746-1596-3-42
Received: 23 June 2008
Accepted: 24 October 2008
This article is available from: http://www.diagnosticpathology.org/content/3/1/42
© 2008 Peschos et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Diagnostic Pathology 2008, 3:42 http://www.diagnosticpathology.org/content/3/1/42
Page 2 of 4
(page number not for citation purposes)
type of cancer is rare, comprising 3% to 5% of all mam-
mary malignancies [6].
To our best knowledge, about 30 cases of mucinous MBC
and about 50 cases of Paget's disease of the male breast
have been until now reported in the English literature [7-
9]. Furthermore, the presentation of the mucinous breast
carcinoma as Paget's disease of the male breast is consid-
ered to be unique.
Case presentation
An 86-year-old man with no medical history presented
with a persistent erythema, oozing and scaling of the left
nipple. The lesion was initially characterized as mammary
Paget's disease, based on clinical signs. Additionally, there
was no history of predisposing factors to breast lesions
such as drug use (i.g. prostate cancer treatment), gyneco-
mastia or hormonal imbalances, such as obesity and/or
testicular disorders. Physical examination revealed a mass
localized in the subareolar area. Fine needle aspiration
biopsy was performed on the mass and malignancy was
revealed on histopathological examination. The diagnosis
was made after the histological examination of a breast
gland segment (14 × 11 × 6 cm in size) covered by a spin-
dle-shaped skin (13 × 9 cm in size) bearing the nipple.
The mass was well circumscribed 5 × 7 × 6 cm in size of
soft and friable consistency with mucoid texture. The
result from the histological examination revealed muci-
nous carcinoma of the breast gland (grade II) (Figure 1).
The diagnosis was based on the presence of large amounts
of extracellular mucin, in the background and detached
epithelial tumor ceels in trabecular and micro papillary
formations. Fibrous stroma was sparse. Immunohisto-
chemical evaluation revealed that the neoplastic cells were
positive for estrogen (ER) (Figure 2) and progesterone
receptors (PR). Therapeutically, after the modified radical
mastectomy chemotherapy and tamoxifen was adminis-
tered.
Discussion
MBC constitutes less than 1% of all breast cancer cases
[1,2]. Mucinous or colloid breast cancer is considered to
be a rare subtype of breast cancer (invasive ductal breast
cancer) and probably slightly more uncommon in men
than in women [10]. Special types such as Paget's disease
of the nipple and mucinous breast cancer in a man are
extremely rare. To our best knowledge this is the first case
reported of mucinous male breast cancer presenting as
Paget's disease of the nipple.
We must emphasize that Paget's disease must be differen-
tiated from other skin disorders, such as eczema, and it is
usually the presence of an underlying lump that indicates
the invasive nature of the lesion. In addition, melanoma
and adenoma of the nipple may rarely mimic Paget's dis-
ease. The correct diagnosis requires histopathologic inter-
pretation, as clinical signs may be similar.
According to the immunohistochemical analysis the can-
cer cells were estrogen and progesterone receptor positive.
Studies have shown that MBC is more likely to be of high
grade at presentation time, affecting mostly elderly males,
with retained expression of ER and PR [2,10-13]. In our
case reported herein, the patient was 86 years old. In spe-
cific, the majority of cancers arising in the male breast are
ER positive although this finding does not correlate with
a better prognosis, as it occurs in women [14,15] Clinical
responses to hormonal therapy have been observed in the
ER+ patients but not in one ER – patient [16]. In women,
ER expression is usually a marker of differentiation and
indicates that the cancer still remains under hormonal
influence. This characteristic would also imply that the
Histological evaluation revealed the presence of mucinous  carcinoma (H + E, × 400) Figure 1
Histological evaluation revealed the presence of 
mucinous carcinoma (H + E, × 400).
The neoplastic cell expressed ER&#945 receptors (DAB  &#215 400) Figure 2
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tumor should be less aggressive and more responsive to
hormone therapy. In men, however, ER-positive tumors
are associated with higher stage disease [15]. Postmeno-
pausal women have been found to have tumors that are
more likely to be hormone receptor expressers as well and
follow a more indolent course [17]. One possibility is that
hormone receptor-positive cancers are a consequence of
aberrant steroid receptor up-regulation in the estrogen-
starved postmenopausal setting. The tumors over express-
ing the steroid receptor may have constitutive activation
of downstream targets. The fact that most cancers arising
in male breasts are ER positive is likely due to the lack of
circulating estrogen in the male system, much like in post-
menopausal women [2]. Apart from steroid receptors
other immunohistochemical differences between male
and female breast cancer must also be considered. For
instance, cases of MBC are less likely to overexpress p53
and Erb-B2, which are associated with survival and cell
proliferative activity than the female counterparts [2].
It appears that MBC has a more aggressive clinical behav-
ior than FBC with a worse outcome when compared stage
for stage [18,19]. Some studies referred to worse progno-
sis in men mainly due to anatomic factors (i.e., paucity of
breast tissue and close tumor proximity to skin and nip-
ple, facilitating dermal lymphatic spread and early
regional and distant metastasis) and delayed diagnosis
[13,18,20]. Usually, in MBC symptoms are often delayed
and the lag time between first symptoms and surgery in
some cases is twice as long as in women [21]. In the case
reported herein, the mammary Paget-like lesion of the
skin bearing the nipple was the main symptom. On the
other hand, numerous studies have shown that breast car-
cinoma in males is not biologically more aggressive than
in females and the prognosis of patients with breast cancer
is the same in male and female patients when disease-spe-
cific survival rate, tumour size and axillary involvement
are compared [22-24].
Modified radical mastectomy, combined with sentinel-
node biopsy by experienced teams, is the standard treat-
ment in case of MBC. Criteria for adjuvant systemic treat-
ment are identical for men and women, although
hormonal therapy (tamoxifen) has a more prominent
place in the adjuvant setting because of the high percent-
age of positive hormone receptors in men [25].
Owing to its infrequent occurrence, knowledge of the eti-
ology, pathology, immunophenotype and behavior of
MBC lags behind that regarding FBC. Numerous studies
have confirmed distinct differences in the genetic basis of
MBC and FBC [26,27]. The poorer prognosis of the male
breast carcinoma might be related to ineffective therapies
which do not consider these differences in the biological
profile of the male tumor. Prognostic and predictive tis-
sutal markers, detected by immunocytochemical methods
and useful for therapeutic programming in the female
breast cancer have a different significance in the male
breast cancer and stress the need for different therapeutic
strategies specific for male breast cancer.
Conclusion
More research is needed on male breast cancer as it
becomes more apparent that it is a different disease than
its female counterpart. This recognition will provide bet-
ter-focused treatment strategies and improved survival,
and will perhaps even provide us with a better under-
standing of breast carcinogenesis both in men and
women.
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